Clinical trials: Infliximab, open to volunteers
Psoriasis, Atopic Dermatitis
Utilization of a Microdevice for Psoriasis and Atopic Dermatitis
This study is being done to test a microdevice, which is a small device designed to test drugs directly on skin conditions like atopic dermatitis (eczema) and psoriasis.
- Trial name
- NCT07352566
- Testing
- In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of California, San Francisco
Acute Kidney Injury, Acute Interstitial Nephritis
Infliximab for Immune Checkpoint Inhibitor Associated AKI
This is a multi-center, 1:1 randomized pilot study examining the efficacy and safety of infliximab 5mg/kg x 1 paired with 2 weeks of prednisone 1mg/kg per day for 2 weeks versus standard-of-care glucocorticoid therapy (prednisone…
- Trial name
- NCT07683975
- Testing
- Infliximab, Prednisone, prednisone (oral)
- Where
- 3 sites in United States
- Volunteers
- 44 people
- Sponsor
- Massachusetts General Hospital
Crohn Disease (CD), IBD (Inflammatory Bowel Disease)
Combining Nutritional Therapy and Anti-TNFα Treatment in Pediatric Patients With Crohn's Disease
Children with Crohn's disease (CD), a type of Inflammatory Bowel Disease (IBD), often face serious health challenges, including poor growth, frequent hospital stays, and long-term medication use.
- Conditions
- Crohn Disease (CD), IBD (Inflammatory Bowel Disease), IBD - Inflammatory Bowel Disease
- Trial name
- DISPENSE-T (NCT07314606)
- Testing
- IFX + mCDED
- Where
- Canada
- Volunteers
- 140 people
- Sponsor
- University of British Columbia
Ulcerative Colitis (UC), IBD-unclassified (IBD-U)
Therapeutic Drug Monitoring for Biological Therapy in Pediatric Inflammatory Bowel Disease
Inflammatory Bowel Diseases (IBD), which include Crohn's disease (CD), ulcerative colitis (UC), and the unclassified form referred to as indeterminate colitis, are most commonly diagnosed during adolescence and early adulthood.
- Trial name
- TDMpIBD (NCT06954311)
- Where
- 10 sites in Austria
- Volunteers
- 120 people
- Sponsor
- Medical University Innsbruck
Crohn Disease
Medical Treatment Versus Surgery in Stricturing Small Bowel Crohn's Disease
The objective of the SMART trial is to compare a combination therapy using azathioprine and subcutaneous infliximab versus ileocecal resection in patients with symptomatic small bowel Crohn's disease.
- Trial name
- SMART (NCT05584228)
- Testing
- Azathioprine + infliximab, Intestinal resection
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Nantes University Hospital
Crohn Disease (CD), Ulcerative Colitis (UC)
the REMONO-CD and the REMONO-UC Studies
Infliximab was the first-in-class anti-TNF agent approved for treating patients with IBD, both for Crohn's disease (CD)1 and ulcerative colitis (UC)2.
- Trial name
- REMONO (NCT07564609)
- Where
- 18 sites in France
- Volunteers
- 420 people
- Sponsor
- University Hospital, Clermont-Ferrand
Ulcerative Colitis, Infliximab
Top Down Versus Step up in Pediatric Ulcerative Colitis
Pediatric Ulcerative Colitis (UC) patients with moderate to severe disease activity at high risk of colectomy. Early use of biologic agents will likely be more effective.
- Conditions
- Ulcerative Colitis, Infliximab, Children
- Trial name
- NCT04999228
- Testing
- Infliximab, Corticosteroids
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Children's Hospital of Fudan University
Mild to Severe Crohns Disease
Preliminary Clinical Study on the Effect of Bacillus Subtilis on the Efficacy of Infliximab in Patients With Crohn's Disease
The goal of this clinical trial is to evaluate the effect of supplementing Bacillus subtilis compared to the control group on the efficacy of Infliximab in patients with Crohn's disease, and to summarize the role of supplementing…
- Trial name
- NCT07123207
- Testing
- Bacillus subtilis Capsules
- Where
- China
- Volunteers
- 24 people
- Sponsor
- The Third Xiangya Hospital of Central South University
Inflammatory Bowel Diseases, Crohn Disease
Conventional vs Biologic Therapy in Pediatric IBD
This combined retrospective-prospective cohort study aims to evaluate the effectiveness, safety, and adverse events of conventional versus biologic therapy in children and adolescents with inflammatory bowel disease at Assiut…
- Conditions
- Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
- Trial name
- NCT07818473
- Volunteers
- 100 people
- Sponsor
- Assiut University
Checkpoint Inhibitor, Pilot Study
Checkpoint Inhibitor Associated Diabetes Mellitus: Early Recognition and Treatment (CERT) Project: A Pilot Study
To find out if taking a drug called infliximab (the "study drug") is safe and effective in reversing insulin dependence in CIADM.
- Conditions
- Checkpoint Inhibitor, Pilot Study, Diabetes Melletus
- Trial name
- NCT07257068
- Testing
- Infliximab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- M.D. Anderson Cancer Center
Crohn Disease
Fecal Microbiota Transplantation in Crohn's Disease as Relay After Anti-TNF Withdrawal
Crohn's disease (CD) is a chronic inflammatory bowel disease. CD pathogenesis remains poorly understood but involves an inappropriate immune response toward an unbalanced gut microbiota in predisposed hosts.
- Trial name
- MIRACLE (NCT04997733)
- Testing
- Fecal Microbiota Transplantation (FMT)
- Where
- France
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
IBD - Inflammatory Bowel Disease, RA - Rheumatoid Arthritis
A Pharmacokinetic-pharmacodynamic Modeling and Simulation Study of Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease
A subcutaneous formulation of infliximab CT-P13 (Remsima, Celltrion) has been approved for clinical use in inflammatory bowel disease (IBD) and rheumatoid arthritis (RA) after demonstration of pharmacokinetic (PK) non-inferiority…
- Trial name
- NCT07120152
- Testing
- Subcutaneous infliximab CT-P13 Remsima®SC
- Volunteers
- 439 people, healthy volunteers welcome
- Sponsor
- Erwin Dreesen
Inflamatory Bowel Disease (Crohn's and Ulcerative Colitis)
Efficacy of Different Biological Treatments in Patients With Inflammatory Bowel Disease After One Year of Treatment in Upper Egypt
To study the efficacy of different biological treatment on patient with inflammatory bowel disease after one year of treatment in upper egypt
- Trial name
- NCT07495644
- Testing
- adalimumab, infliximab, ustekinumab, golimumab, and vedolizumab
- Volunteers
- 95 people
- Sponsor
- Assiut University
Colitis, Ulcerative
Comparison of Medical RESCUE Strategies for Patients With Steroid-refractory Acute Severe Ulcerative Colitis
This study aims to examine patients with acute severe UC who are refractory to intravenous corticosteroids and determine whether a strategy of using upadacitinib first followed by infliximab in upadacitinib non-responders is…
- Trial name
- RESCUE UC (NCT06660693)
- Testing
- Upadacitinib Oral Product
- Where
- Canada
- Volunteers
- 134 people
- Sponsor
- McMaster University
Colitis
Efficacy and Safety of Infliximab for Immune Checkpoint Inhibitor Induced Colitis
The goal of this clinical trial is to assess whether the early introduction of biological treatment with a TNF-alpha inhibitor (infliximab) in addition to corticosteroids for severe ir-colitis/diarrhoea will reduce the time to…
- Trial name
- iCaD (NCT05947669)
- Testing
- Infliximab, Methylprednisolone, Prednisolone
- Where
- 3 sites in Denmark, United Kingdom
- Volunteers
- 195 people
- Sponsor
- Odense University Hospital
IBD, Ulcerative Colitis
Ibd CAncer and seRious Infections in France (I-CARE 2)
This is a French prospective longitudinal observational multicentre cohort study. Primary objective : to assess prospectively the presence and the extent of safety concerns (cancer, serious infections, arterial and venous…
- Conditions
- IBD, Ulcerative Colitis, Crohn Disease
- Trial name
- I-CARE 2 (NCT06089590)
- Testing
- Non-interventional
- Where
- 2 sites in France
- Volunteers
- 6,000 people
- Sponsor
- Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
Crohn Disease
PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease
There are currently three classes of biologic treatments approved in Canada for the management of moderate-to-severe Crohn's disease: anti-tumor necrosis factor [TNF] alpha, anti-integrin, and anti-interleukin [IL]-23 targeted…
- Trial name
- PATHFINDER (NCT05928039)
- Testing
- TNFa Antagonist - Infliximab, TNFa Antagonist - Adalimumab, Anti-IL12/23 or anti-IL23 - Ustekinumab
- Where
- 23 sites in Canada
- Volunteers
- 210 people
- Sponsor
- University of Calgary
Inflammatory Bowel Disease, Crohn Disease
High Dose Interval Vitamin D Supplementation in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy
The investigators will be administering oral high dose interval vitamin D, concurrently when participants are receiving biologic therapy for their inflammatory bowel disease.
- Conditions
- Inflammatory Bowel Disease, Crohn Disease, Ulcerative Colitis, Vitamin D Deficiency
- Trial name
- NCT04331639
- Testing
- vitamin D3
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Boston Children's Hospital
Crohn's Diseases, Crohn's Disease in Pediatric Patient
The Efficacy and Safety of Infliximab Combination With Azathioprine in Crohn's Disease in Children
The goal of this clinical trial is to investigate whether there are significant differences in the efficacy of infliximab monotherapy and combined azathioprine therapy in treating pediatric Crohn's disease, as well as whether…
- Trial name
- NCT07424040
- Testing
- Infliximab combined with azathioprine therapy, Infliximab monotherapy
- Where
- 4 sites in China
- Volunteers
- 154 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Spondyloarthropathies, Ankylosing Spondylitis
Faecal Analyses in Spondyloarthritis Therapy
This study evaluates the intestinal microbiome and disease activity in patients with spondyloarthropathies receiving immunosuppressive therapy.
- Trial name
- FAST (NCT03839862)
- Testing
- TNF-inhibition
- Where
- Sweden
- Volunteers
- 50 people
- Sponsor
- Region Skane